Shanghai Serum Bio-Technology Co. Ltd. A (688163) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Shanghai Serum Bio-Technology Co. Ltd. A ¥4.61, price ¥38.27, upside -88.0%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Shanghai Serum Bio-Technology Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
54‑month range ¥11.28 – ¥51.40 · fair‑value band ¥4.01 – ¥6.85 · the ¥38.27 price screens above the ¥4.61 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Shanghai Serum Bio-Technology Co. Ltd. A in your weekly email
Every Wednesday you see whether Shanghai Serum Bio-Technology Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sales of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.
Stock analysis
Shanghai Serum Bio-Technology Co. Ltd. A (688163) currently trades at ¥38.27, while our model-based Fair Value estimate is ¥4.61, implying the stock looks roughly 729.9% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥8.14 per share, and 0 of the 23 models we run sit above the ¥38.27 price.
Bear case: the Dividend Discount group reads lowest at ¥2.97, and 23 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥4.01 (bear) to ¥6.85 (bull), the price of ¥38.27 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Shanghai Serum Bio-Technology Co. Ltd. A reported revenue of 196M CNY in FY2025 versus 209M CNY in FY2021, a compound −1.5%/yr. Reported net income was 51.8M CNY in FY2025, compounding −9.3%/yr from FY2021.
Key figures
Market cap 4.1B CNY (≈ $618M) · P/E ratio 83.2 · P/S ratio 22.0 · EPS (TTM) ¥0.4600 · Dividend yield 1.0% · Net margin 26.4% · Return on equity 4.4% · Return on assets (EBIT) 8.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 79% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −88%, 688163 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥0.4100 to ¥10.53). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥4.01Fair Value ¥4.61Bull ¥6.85
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.0585 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−9.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.0%
Dividend (yield on the price)1.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.45% → 28%
Compare Shanghai Serum Bio-Technology Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside−88% · Bottom 25%
Profitability
Return on equity (TTM)4% · Above median
Return on assets3% · Top 25%
Net margin (TTM)25% · Top 25%
Operating margin (TTM)−6% · Below median
Growth and dividend
Revenue growth6% · Above median
Dividend yield (TTM)1.0% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)83.2× · Priciest 25%
P/B3.72× · Priciest 25%
P/S (TTM)20.95× · Priciest 25%
P/FCF668.1× · Priciest 25%
EV/EBITDA60.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)29· sector 0
PAST (return on equity)18· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)20· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shanghai Serum Bio-Technology Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688163
Frequently asked questions
Is Shanghai Serum Bio-Technology Co. Ltd. A (688163) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥4.61 versus a price of ¥38.27, about −88% upside (overvalued).
What is the fair value of 688163?
Our model-based fair value for Shanghai Serum Bio-Technology Co. Ltd. A is ¥4.61 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥38.27.
What is the quality score of 688163?
Shanghai Serum Bio-Technology Co. Ltd. A has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
Our model-based price target is the fair value of ¥4.61 (as of Sep 23, 2026) from 23 valuation models. Cautious scenario ¥4.01, optimistic scenario ¥6.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Serum Bio-Technology Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥4.61, about −88% upside versus a price of ¥38.27 (overvalued). Cautious scenario ¥4.01, optimistic scenario ¥6.85. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
Shanghai Serum Bio-Technology Co. Ltd. A reported trailing-twelve-month revenue of about 198M CNY (latest available figure, as of Sep 23, 2026).
Does Shanghai Serum Bio-Technology Co. Ltd. A pay a dividend?
Shanghai Serum Bio-Technology Co. Ltd. A currently shows a dividend yield of about 0.99% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Serum Bio-Technology Co. Ltd. A it is ¥4.61 per share (as of Sep 23, 2026), against a price of ¥38.27. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai Serum Bio-Technology Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 688163 trades above its calculated fair value: price ¥38.27, fair value ¥4.61, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688163?
No. The price is what the market pays today (¥38.27); the fair value is what the company's own numbers justify (¥4.61). For Shanghai Serum Bio-Technology Co. Ltd. A the two are ¥33.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Serum Bio-Technology Co. Ltd. A worth?
The market values Shanghai Serum Bio-Technology Co. Ltd. A at about 4.1B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥38.27; our models calculate a fair value of ¥4.61 per share.
What do the bullish and bearish scenarios say about 688163?
Our models span a range for Shanghai Serum Bio-Technology Co. Ltd. A: cautious scenario ¥4.01, base ¥4.61, optimistic ¥6.85 per share (as of Sep 23, 2026, price ¥38.27). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688163?
Shanghai Serum Bio-Technology Co. Ltd. A trades at a price-to-earnings ratio of 83.2 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥4.61 is built from several models across several years. Other multiples: P/B 3.7, P/S 21.0, EV/EBITDA 60.4.
How solid is the balance sheet of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
Balance-sheet figures for Shanghai Serum Bio-Technology Co. Ltd. A (as of Sep 23, 2026): return on equity 4.4%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 688163 from its 52-week high?
Shanghai Serum Bio-Technology Co. Ltd. A trades at ¥38.27, about 26% below its 52-week high of ¥51.40 and 79% above the low of ¥21.42 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥4.61 is for.
Which stocks are comparable to Shanghai Serum Bio-Technology Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Serum Bio-Technology Co. Ltd. A stock attractive at the current price?
The data as of Sep 23, 2026: price ¥38.27, calculated fair value ¥4.61 (−88%), Quality Score 56/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688163 calculated?
We run Shanghai Serum Bio-Technology Co. Ltd. A through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥4.61, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Shanghai Serum Bio-Technology Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
The closing price on Sep 23, 2026 was ¥38.27. Our model-based fair value is ¥4.61, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Serum Bio-Technology Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥6.85). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Shanghai Serum Bio-Technology Co. Ltd. A
How large is the market capitalisation of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
The market capitalisation of Shanghai Serum Bio-Technology Co. Ltd. A is 4.1B CNY (≈ $618M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
The price-to-sales ratio of Shanghai Serum Bio-Technology Co. Ltd. A is 22.0 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
Earnings per share at Shanghai Serum Bio-Technology Co. Ltd. A are ¥0.4600 (price ÷ EPS = P/E 83.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
The dividend yield of Shanghai Serum Bio-Technology Co. Ltd. A is 1.0% (payout 82.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
The net margin of Shanghai Serum Bio-Technology Co. Ltd. A is 26.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
The return on equity (ROE) of Shanghai Serum Bio-Technology Co. Ltd. A is 4.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
On an EBIT basis the return on assets of Shanghai Serum Bio-Technology Co. Ltd. A is 8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
The operating margin of Shanghai Serum Bio-Technology Co. Ltd. A is −6.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
Revenue at Shanghai Serum Bio-Technology Co. Ltd. A is growing +5.7% versus a year earlier (3y avg +4.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shanghai Serum Bio-Technology Co. Ltd. A (688163)?
Earnings per share at Shanghai Serum Bio-Technology Co. Ltd. A are growing −66.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shanghai Serum Bio-Technology Co. Ltd. A (688163) generate?
The free cash flow of Shanghai Serum Bio-Technology Co. Ltd. A is 925K CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Shanghai Serum Bio-Technology Co. Ltd. A in the live analysis
One click puts Shanghai Serum Bio-Technology Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
